Literature DB >> 28757255

Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide.

Takanori Kanazawa1, Mami Kaneko2, Takaki Niide2, Fuminari Akiyama2, Shino Kakizaki2, Hisako Ibaraki2, Shunsuke Shiraishi2, Yuuki Takashima2, Toyofumi Suzuki3, Yasuo Seta2.   

Abstract

Recently, nose-to-brain delivery is a highly versatile route, which, in combination with novel drugs being developed for treating intractable CNS diseases, is a promising approach for the treatment of disorders. Furthermore, nano-sized drug carriers may improve nose-to-brain drug delivery by their capability to increase the transmucosal penetration of the drugs across nasal mucosal tissue barrier. However, there is still not enough information regarding mechanism of absorption pathway from nasal cavity to brain using nanocarriers. In this study, to investigate the nose-to-brain transport pathway using nanocarriers, the distribution in whole brain, nasal mucosa, and trigeminal nerve after intranasal administration of two kinds of nanocarriers which have hydrophobic or hydrophilic moiety. We used CHHRRRRHHC peptide (CH2R4H2C) as basic peptide carriers, and modified with stearic acid (STR) as a hydrophobic moiety (STR-CH2R4H2C) or polyethylene glycol (PEG)-based block copolymer (PEG-PCL) as hydrophilic moiety (PEG-PCL-CH2R4H2C). The nose-to-brain drug delivery can be improved by using STR-CH2R4H2C and PEG-PCL-CH2R4H2C as carriers. Specifically, hydrophobic STR-CH2R4H2C is more suitable for the transport of drugs targeting the forebrain, while PEG-PCL-modified CH2R4H2C is more suitable for transporting drugs targeting the hindbrain or whole brain tissue. In conclusion, the results of this study support the possibility that drug delivery pathways can be controlled depending on the properties of different carrier complexes.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain delivery; Brainstem; Nose-to-brain; Olfactory bulb; Peptide-based carrier; Trigeminal nerve

Mesh:

Substances:

Year:  2017        PMID: 28757255     DOI: 10.1016/j.ijpharm.2017.07.077

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Using nanotechnology to deliver biomolecules from nose to brain - peptides, proteins, monoclonal antibodies and RNA.

Authors:  Mireya L Borrajo; María José Alonso
Journal:  Drug Deliv Transl Res       Date:  2021-11-03       Impact factor: 4.617

Review 2.  Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic.

Authors:  Vladimir A Ljubimov; Arshia Ramesh; Saya Davani; Moise Danielpour; Joshua J Breunig; Keith L Black
Journal:  Adv Drug Deliv Rev       Date:  2021-11-20       Impact factor: 17.873

Review 3.  Membrane Internalization Mechanisms and Design Strategies of Arginine-Rich Cell-Penetrating Peptides.

Authors:  Minglu Hao; Lei Zhang; Pu Chen
Journal:  Int J Mol Sci       Date:  2022-08-12       Impact factor: 6.208

Review 4.  Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects.

Authors:  Amarjitsing Rajput; Prashant Pingale; Vividha Dhapte-Pawar
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988

Review 5.  Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting.

Authors:  Fabio Sonvico; Adryana Clementino; Francesca Buttini; Gaia Colombo; Silvia Pescina; Silvia Stanisçuaski Guterres; Adriana Raffin Pohlmann; Sara Nicoli
Journal:  Pharmaceutics       Date:  2018-03-15       Impact factor: 6.321

6.  Therapeutic Effects in a Transient Middle Cerebral Artery Occlusion Rat Model by Nose-To-Brain Delivery of Anti-TNF-Alpha siRNA with Cell-Penetrating Peptide-Modified Polymer Micelles.

Authors:  Takanori Kanazawa; Takumi Kurano; Hisako Ibaraki; Yuuki Takashima; Toyofumi Suzuki; Yasuo Seta
Journal:  Pharmaceutics       Date:  2019-09-15       Impact factor: 6.321

Review 7.  Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier.

Authors:  David Lee; Tamara Minko
Journal:  Pharmaceutics       Date:  2021-11-30       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.